Risk factors for failure of Helicobacter pylori therapy -: results of an individual data analysis of 2751 patients

被引:170
作者
Broutet, N
Tchamgoué, S
Pereira, E
Lamouliatte, H
Salamon, R
Mégraud, F
机构
[1] Univ Bordeaux 2, Bacteriol Lab, Unite Epidemiol Malad Digest, F-33076 Bordeaux, France
[2] Hop St Andre, Serv Gastroenterol, Bordeaux, France
[3] Univ Bordeaux 2, INSERM, U330, Inst Sante Publ Dev, F-33076 Bordeaux, France
关键词
D O I
10.1046/j.1365-2036.2003.01396.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To study risk factors for failure of Helicobacter pylori eradication treatment. Methods: Individual data from 2751 patients included in 11 multicentre clinical trials carried out in France and using a triple therapy, were gathered in a unique database. The 27 treatment regimens were regrouped into four categories. Results: The global failure rate was 25.8%[95% CI: 24-27]. There was a difference in failure rate between duodenal ulcer patients and non-ulcer dyspeptic patients, 21.9% and 33.7%, respectively (P < 10(-6) ). In a random-effect model, the risk factors identified for eradication failure in duodenal ulcer patients (n = 1400) were: to be a smoker, and to have received the group 4 treatment, while to receive a 10 day treatment vs. 7 days protected from failure. In non-ulcer dyspeptic patients (n = 913), the group 2 treatment was associated with failure. In both groups, age over 60 was associated with successful H. pylori eradication. There were less strains resistant to clarithromycin in duodenal ulcer patients than in non-ulcer dyspeptic patients. Clarithromycin resistance predicted failure almost perfectly. Conclusion: Duodenal ulcer and non-ulcer dyspeptic patients should be managed differently in medical practice and considered independently in eradication trials.
引用
收藏
页码:99 / 109
页数:11
相关论文
共 38 条
[1]   Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia [J].
Blum, AL ;
Talley, NJ ;
O'Moráin, C ;
van Zanten, SV ;
Labenz, J ;
Stolte, M ;
Louw, JA ;
Stubberöd, A ;
Theodórs, A ;
Sundin, M ;
Bolling-Sternevald, E ;
Junghard, O .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1875-1881
[2]   cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia [J].
Broutet, N ;
Marais, A ;
Lamouliatte, H ;
De Mascarel, A ;
Samoyeau, R ;
Salamon, R ;
Mégraud, F .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (04) :1319-1322
[3]   Role of tight junctions in establishing and maintaining cell polarity [J].
Cereijido, M ;
Valdés, J ;
Shoshani, L ;
Contreras, RG .
ANNUAL REVIEW OF PHYSIOLOGY, 1998, 60 :161-177
[4]  
DAMMANN HG, 1997, GUT S1, V41, P95
[5]  
DELCHIER JC, 2001, GASTROENTEROL CLIN B, V25, pA8
[6]   Classification and grading of gastritis - The updated Sydney System [J].
Dixon, MF ;
Genta, RM ;
Yardley, JH ;
Correa, P ;
Batts, KP ;
Dahms, BB ;
Filipe, MI ;
Haggitt, RC ;
Haot, J ;
Hui, PK ;
Lechago, J ;
Lewin, K ;
Offerhaus, JA ;
Price, AB ;
Riddell, RH ;
Sipponen, P ;
Solcia, E ;
Watanabe, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) :1161-1181
[7]   Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers [J].
Hamlet, A ;
Thoreson, AC ;
Nilsson, O ;
Svennerholm, AM ;
Olbe, L .
GASTROENTEROLOGY, 1999, 116 (02) :259-268
[8]  
Hosmer D., 1989, Applied logistic regression, P82
[9]  
Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047
[10]  
HUANG JQ, 1998, AM J GASTROENTEROL, V93, P1639